Marshall Wace
ORMP icon

Marshall Wace’s Oramed Pharmaceuticals ORMP Stock Holding History

Marshall Wace’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$883K Buy
259,611
+556
+0.2% +$1.89K ﹤0.01% 2201
2025
Q4 		$738K Buy
+259,055
New +$668K ﹤0.01% 2078
2024
Q4 		– Sell
-22,527
Closed -$55K – 2898
2024
Q3 		$55K Buy
+22,527
New +$54.9K ﹤0.01% 2414
2023
Q2 		– Sell
-10,553
Closed -$23K – 2836
2023
Q1 		$23K Sell
10,553
-26,846
-72% -$85.3K ﹤0.01% 2568
2022
Q4 		$450K Buy
37,399
+8,990
+32% +$69.9K ﹤0.01% 2413
2022
Q3 		$185K Buy
28,409
+8,900
+46% +$72K ﹤0.01% 3100
2022
Q2 		$90K Buy
+19,509
New +$104K ﹤0.01% 3289
2021
Q2 		– Sell
-11,563
Closed -$117K – 2962
2021
Q1 		$117K Sell
11,563
-25,069
-68% -$206K ﹤0.01% 2345
2020
Q4 		$155K Sell
36,632
-22,016
-38% -$71.6K ﹤0.01% 1771
2020
Q3 		$153K Buy
58,648
+10,388
+22% +$36.2K ﹤0.01% 1489
2020
Q2 		$170K Sell
48,260
-29,101
-38% -$97.7K ﹤0.01% 1432
2020
Q1 		$235K Sell
77,361
-36,345
-32% -$159K ﹤0.01% 1153
2019
Q4 		$586K Buy
+113,706
New +$426K ﹤0.01% 1122

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $5.76B AUM 24.57% 1-Year Est. Return

Marshall Wace's ORMP Position: Q1 2026 in Review

Marshall Wace increased its Oramed Pharmaceuticals (ORMP) stake by 0.21% in Q1 2026, buying an estimated $1.89K and bringing the position to 259,611 shares worth $883K. The position accounts for ﹤0.01% of the portfolio, ranked #2201.

Marshall Wace first reported a position in ORMP in Q4 2019 and has held it in 13 quarters since. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Marshall Wace held 259,611 shares of Oramed Pharmaceuticals worth $883K as of Q1 2026.
  • Marshall Wace bought 556 Oramed Pharmaceuticals shares in Q1 2026, an estimated $1.89K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2201 holding.
  • Marshall Wace first reported a position in Oramed Pharmaceuticals in Q4 2019 and has held it in 13 quarters since.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.